Gland Pharma, operating within the Pharmaceuticals & Biotechnology sector, currently holds a Mojo Score of 44.0 with a market cap grade of 3. The adjustment in its evaluation was recorded on 19 Nov 2025, following a prior status dated 18 Nov 2025. The stock price closed at ₹1,788.00, down by 1.47% from the previous close of ₹1,814.60, with intraday fluctuations between ₹1,786.00 and ₹1,822.05. Over the past 52 weeks, the stock has traded within a range of ₹1,200.00 to ₹2,130.00.
Examining the quality parameter, Gland Pharma’s financial performance over recent quarters has been largely flat. The company reported a Profit Before Tax (PBT) excluding other income of ₹199.76 crores for Q2 FY25-26, which is approximately 14.8% lower than the average of the preceding four quarters. This subdued profitability trend is further underscored by a five-year compound annual growth rate (CAGR) of operating profit at -6.65%, indicating challenges in sustaining long-term growth momentum. Additionally, the company’s Return on Equity (ROE) stands at 8.3%, a figure that suggests moderate efficiency in generating shareholder returns relative to peers in the pharmaceutical industry.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- Fresh momentum detected
- Explosive short-term signals
- Early wave positioning
From a valuation perspective, Gland Pharma’s Price to Book Value ratio is currently 3.1, which places the stock at a premium relative to its historical averages and peer group valuations. This elevated valuation metric suggests that the market is pricing in expectations of future growth or other qualitative factors despite the flat recent financial results. The Price/Earnings to Growth (PEG) ratio of 2.6 further indicates that the stock’s price may be reflecting growth prospects that are not fully supported by the underlying earnings trajectory, especially when considering the modest profit growth of 14.3% over the past year.
Financial trend analysis reveals a mixed picture. While the stock has generated a return of 0.79% over the last year, this performance lags behind the broader Sensex index, which has delivered a 9.48% return over the same period. Over longer horizons, the disparity widens, with the Sensex showing a 37.31% return over three years and 91.65% over five years, whereas Gland Pharma’s comparable data is not available for these periods. The company’s debtor turnover ratio for the half-year stands at a low 0.37 times, indicating slower collection cycles which could impact liquidity. On a positive note, the company maintains a low average debt-to-equity ratio of zero, reflecting a conservative capital structure with minimal leverage.
Technical indicators have played a significant role in the recent adjustment of Gland Pharma’s evaluation. The technical trend has shifted from mildly bullish to mildly bearish, influenced by several key metrics. The Moving Average Convergence Divergence (MACD) on both weekly and monthly charts signals a mildly bearish outlook. Similarly, the Know Sure Thing (KST) indicator aligns with this bearish sentiment on weekly and monthly timeframes. Bollinger Bands present a mixed view, with weekly readings bearish but monthly readings mildly bullish. The Relative Strength Index (RSI) shows no clear signal on either weekly or monthly charts, while the On-Balance Volume (OBV) suggests mild bearishness. The Dow Theory analysis indicates no definitive trend on the weekly chart and a mildly bearish stance monthly. Daily moving averages, however, retain a mildly bullish posture, reflecting some short-term support.
These technical nuances highlight a period of consolidation and uncertainty for Gland Pharma’s stock price, with short-term indicators showing caution while some longer-term signals remain neutral or mildly positive. This complexity in technical readings has contributed to the revision in the company’s overall evaluation.
Is Gland Pharma your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- Better alternatives suggested
- Cross-sector comparison
- Portfolio optimization tool
Institutional ownership in Gland Pharma remains significant at 40.54%, indicating that a substantial portion of the stock is held by investors with advanced analytical capabilities and resources. This level of institutional interest often reflects confidence in the company’s fundamentals or strategic positioning, even amid fluctuating market conditions.
In summary, the adjustment in Gland Pharma’s investment evaluation is the result of a combination of factors. The quality parameter reflects flat recent financial results and subdued long-term operating profit growth. Valuation metrics indicate a premium pricing relative to peers and historical norms. Financial trends show modest returns relative to the broader market and some liquidity concerns. Technical indicators have shifted towards a more cautious stance, with several key signals turning mildly bearish. Together, these elements have led to a revision in the company’s score, signalling a recalibration of its investment profile.
Investors analysing Gland Pharma should consider these multifaceted aspects when assessing the stock’s potential within the Pharmaceuticals & Biotechnology sector. The interplay of valuation, financial performance, and technical trends underscores the importance of a comprehensive approach to investment decisions in this space.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
